Professionals 210 Users Online

Pulmonary Fibrosis Treatment Market

Growing Incidence of Chronic Pulmonary Disorders and Increasing Demand for Monotherapy as Treatment Module is Expected to Drive Market Growth

Pulmonary Fibrosis Treatment Market Segmented By Monotherapy, Combination Therapy with Idiopathic Pulmonary Fibrosis (IPF), Familial PF Indication

Pulmonary Fibrosis Treatment Market Outlook (2023-2033)

Worldwide revenue from the pulmonary fibrosis treatment market stands at US$ 2.9 Bn in 2022, with the global market estimated to surge ahead at a CAGR value of 5.9% to reach a valuation of US$ 5.6 Bn by the end of 2033.

Market Size (2022)

US$ 2.9 Bn

Projected Market Value (2033)

US$ 5.6 Bn

Global Market Growth Rate (2023-2033)

5.9% CAGR

Market Share of Top 5 Countries


As assessed by Persistence Market Research, monotherapy segment is expected to hold a market value of US$ 4.0 Bn by 2033. Overall, pulmonary fibrosis treatment market sales account for approximately 17.5% revenue share in the global chronic obstructive pulmonary disease treatment market, which was valued at around US$ 16.7 Bn in 2022.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Sales Analysis of Pulmonary Fibrosis Treatment Market from 2014 to 2022 Vs Market Outlook for 2023 to 2033

The global market for pulmonary fibrosis treatment recorded a historic CAGR of 6.0% in the last 8 years from 2014 to 2022.

Primary cause of pulmonary fibrosis is when scar in Lung tissue begins to occur, an interstitial lung disease that decreases the lung's capacity to exchange oxygen. It is an incurable illness that cannot be treated. Drugs used to treat pulmonary fibrosis can aid in managing the condition for nearly two and five years.

In the western world, there is a lot of research being done to determine the cause of pulmonary fibrosis and potential breakthrough therapies for its effective treatment. Many academic institutions and pharmaceutical and biopharmaceutical firms are working to develop innovative pulmonary fibrosis therapeutic pathways.

For example in 2019, The Pulmonary Fibrosis Foundation (PFF) announced launch of PRECISIONS, a research aimed to support the precision medicine for idiopathic pulmonary fibrosis (IPF). This new technology will enable scientist to isolate and examine specific at genetic and molecular level thus creating novel therapies for IPF patients. This ongoing research study has received a grant of US$ 22 million from National Institute of the Health (NIH) and Three Lake Partners, a philanthropic family organizations.

Furthermore, the a unique status was granted to biologics and drugs intended to treat, diagnose, and prevent diseases in the U.S. by the U.S. FDA orphan drug designation programs. The FDA orphan drug designation offers an exclusivity period of seven-year marketing for competition and certain incentives including tax credits, federal grants, and a waiver of PDUFA filing fees.

Companies that received the orphan drug designation for their products benefitted from protocol assistance, marketing authorization, financial incentives, and national incentives provided by the European Commission.

  • In August 2019, DWN12088, oral IPF therapy of Daewoong Pharmaceutical received orphan drug designation from UFDA.

Moreover, Diagnosis rate and treatment seeking rate in the middle income countries is below par as compared to developed countries. Misdiagnosis is affecting the diagnosis rate adversely and is reflecting the same in treatment seeking rate. Limited availability of new treatment options such as Ofev and Esbriet further limit the potential growth of the pulmonary fibrosis treatment market.

The global pulmonary fibrosis treatment market is thus likely to show high growth over the coming years a CAGR value of 5.9% and reach a global market size of US$ 5.6 Bn by 2033.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

How Can Product Manufacturers Grow in Market?

Rising Drug Approvals and Launches

Pulmonary fibrosis treatment drug manufacturers are majorly focused on building the strong pipeline for the future launch with improved compliance in patient. Various manufacturers are looking to develop novel therapy for the treatment of pulmonary fibrosis. PMR estimates that various large molecule (biologics) are expected to be evaluated for the pulmonary fibrosis treatment with potential launch of few in the upcoming years. The manufacturers making pulmonary fibrosis drugs are engaging in various research activities and drug approval processes in various region to generate the revenue.

For example,

  • In March 2020, Esbriet (pirfenidone) drug by Roche, received Breakthrough Therapy Designation (BTD) from U.S.FDA. The drug is intended for use in adults who are suffering from unclassifiable interstitial lung disease (uILD).
  • Galecto’s GB0139, in August 2020, has being designated as Orphan Drug (ODD) from both U.S. FDA and the European Medicine Agency (EMA). The drug has been developed for the novel treatment for idiopathic Pulmonary Fibrosis (IPF)

The introduction of these new drug is expected to result in high adoption rates, which will in turn drive market growth during the forecast period.

Many companies are focused on developing advanced pulmonary fibrosis treatment. While some companies are carrying out acquisitions in order to expand its portfolio, some are trying to expand their regional presence and tap emerging markets.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Can Demand for Be Affected in Any Way?

Limited Treatment Options & Comorbidities Interfering with Treatment

The management of pulmonary fibrosis has a restricted range of treatment choices. Up until 2014, treating diseases off-label with immunosuppressive medications like corticosteroids was the only way to treat disease. The introduction of Ofev (nintedanib) and Esbriet (Pirfenidone) by Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech, respectively, altered the way pulmonary fibrosis is treated in western nations.

Higher price of drugs and lower per capita spending on treating pulmonary fibrosis and low availability of drugs like Ofev and Esbriet is one of the major restraining factors. Patients in poor and middle income nations frequently receive their diagnoses at a later stage, which results in a higher number of comorbidities and makes illness management challenging. Comorbidities such as pulmonary hypertension is observed in more than 60% of patients with pulmonary fibrosis.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Insights

Why the U.S. Market is Booming?

“Increasing Smoking Prevalence and pulmonary disorders in U.S.”

The U.S. accounted for 98.8% market share in the North America market in 2022, and a similar trend is expected over the forecast period.

The prevalence of smoking is increasing in developed as well as developing countries. As per WHO, the prevalence of smoking is higher in countries with upper middle income as compared to high income countries. The population of secondhanded/passive smokers is also increasing. Although the current statistics indicates decrease in the percentage of smokers but rapid increase in the population has significantly affected lowering the percentage of smoker’s number and proportion of the smokers who quit smoking.

  • For Instances, As per Centres for Disease Control and Prevention more than 14% (~34.5 million) adult in the U.S. smoke tobacco as of 2019.

Will Germany Be a Lucrative Market for Pulmonary Fibrosis Treatment?

“Medical Device Industry raising Demand for Pulmonary fibrosis treatment”

Germany held around 27.2% market share of the Europe market in 2022.

Germany continues to have the largest adoption rate due to rising geriatric population. Industrial advancement, geriatric population and rise in research and development spending are the major factors boosting the demand for pulmonary fibrosis treatment market in Germany.

The risk associated with pulmonary related problem increases by age. Increasing number of geriatric population is one of the major factors that is driving the pulmonary fibrosis treatment market.

  • For instance, According to the World Health Aging 2020 highlights by the United Nations Department of Economic and Social Affairs, in 2020, population aged 65 years and above for Germany was 21.7 %. Population ages 65 and above as a percentage of the total population.

How is Japan Emerging as a Prominent Market?

“Huge Manpower and Production Capacity Drive the Market”

Japan held the largest market share of about 59.3% of the East Asia market in 2022.

Countries such as Japan have abundance of working and qualified manpower at reasonable costs thereby increasing the scope for attracting outsourcing of many projects. Moreover, Japan is a crucial export market for American pharmaceuticals as it is the third-largest pharmaceutical market in the world. Increased budgets and funding, R&D, creating public and private corporations and attracting foreign direct investments largely drives this market.

The healthcare sector has been supported by the Government of Japan ("GOJ") since 2013 as a key growth driver under the nation's economic revival and growth strategy. Such promotions are expected to drive the Japanese market to generate more revenue.

Category-wise Insights

Which Therapy Type is Driving Growth of the Global Market?

“Huge Utilization of Monotherapy for Pulmonary Diseases across Regions”

The monotherapy segment held around 72.2% share of the total market in 2022.

Monotherapy is treatment with single drug at one time. For pulmonary fibrosis treatment, various drugs are being used as monotherapy. Pirfenidone, nintedanib and prednisone (corticosteroid) are the major candidates which are being used as monotherapy for the pulmonary fibrosis treatment.

Owed to the benefits that it offers including absence of drug interactions, lower cost, improved seizure control and reduced side effects amongst others, monotherapy has largely been used compared to other therapies. This factor drive the market growth.

Which Indication for Pulmonary Fibrosis Treatment are highly adopted?

“Growing Incidence of Idiopathic Pulmonary Fibrosis (IPF)”

Idiopathic Pulmonary Fibrosis (IPF) segment by indication held a larger share of about 91.8% with a market value of around US$ 2.7 Bn in 2022. Rising incidence of Idiopathic Pulmonary Fibrosis (IPF) increase the administration of pulmonary treatment. Due to its high quality and biological compatibility, this material is highly used and contribute the largest to the growth of this market.

  • According to Lung Org, idiopathic pulmonary fibrosis, or IPF, affects up to 207 thousand people in the U.S. alone. Additionally, more than 55 thousand new cases of IPF are identified every year.

From which Distribution Channel, High Revenue is Generated for Pulmonary Fibrosis Treatment?

“Retail Pharmacy are at High Pace.”

Retail Pharmacy held the largest market share of around 51.8% in 2022. Easy availability of drug formulation of prescription and availability of over-the-counter drugs in retail pharmacies drive the pulmonary fibrosis treatment market and is expected to do so in future.

Competitive Landscape

Several leading players in the pulmonary fibrosis treatment industry have participated in consolidation activities such as mergers and acquisitions. Another significant approach noticed in the industry is the expansion of corporate collaborations in order to boost their pulmonary fibrosis treatment services.

For instance:

  • In October 2020, Cipla introduced generic version Nintedanib for treatment of Idiopathic Pulmonary Fibrosis (IPF). In India, this drug will be marketed under band name Ninitb. Nintedanib will be available in two formulations of 100 mg & 150 mg.

Pulmonary Fibrosis Treatment Industry Report Scope



Forecast Period


Historical Data Available for


Market Analysis

USD Million for Value

Key Countries Covered

  • U.S.
  • Canada
  • Brazil
  • Argentina
  • Mexico
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Russia
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Turkey
  • GCC
  • North Africa
  • South Africa

Key Market Segments Covered

  • Therapy Type
  • Indication
  • End-User
  • Region

Key Companies Profiled

  • F. Hoffman - La Roche Ltd.
  • Boehringer Ingelheim
  • International GmbH
  • Cipla Ltd (Cipla)
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • FibroGen Inc.,
  • Galecto, Inc.

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Key Segments Covered in Pulmonary Fibrosis Treatment Industry Research

By Therapy Type:

  • Monotherapy
    • Pirfenidone Therapy
    • Nintedanib Therapy
    • Corticosteroids Therapy
  • Combination Therapy
    • Pirfenidone & Corticosteroid
    • Nintedanib & Corticosteroid
    • Pirfenidone & Antitussive
    • Others
  • Symptomatic Treatment

By Indication:

  • Idiopathic Pulmonary Fibrosis (IPF)
  • Familial PF
  • Others

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Mail Order Pharmacy

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

- Companies Covered in This Report -

  • F. Hoffman - La Roche Ltd.
  • Boehringer Ingelheim
  • International GmbH
  • Cipla Ltd (Cipla)
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • FibroGen Inc.,
  • Galecto, Inc.

- Frequently Asked Questions -

The global market is currently valued at around US$ 2.9 Bn in 2022.

Sales of pulmonary fibrosis treatment market are set to witness a high growth rate of 5.9% and be valued at US$ 5.6 Bn by 2033.

Demand for market increased at 6.0% CAGR from 2014 to 2022.

The U.S., Germany, U.K., Japan and France account for most demand for pulmonary fibrosis treatment, currently holding 88.8% market share.

The U.S. accounts for around 98.8% share of the North American market.

Rising geriatric population, new drug launches, gaining incentives through the orphan drug designation and outbreak of COVID19 has created a vast opportunity for healthcare industries to expand are some of the key trends in this market.

India is projected to grow with a CAGR of 8.2% in the forecast period.

Germany held around 27.2% market share of the Europe market in 2022.

F. Hoffman - La Roche Ltd., Boehringer Ingelheim International GmbH and Bristol-Myers Squibb Company are the top three players within the pulmonary fibrosis treatment industry.

Japan held the largest market share of about 59.3% of the East Asia market in 2022.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate